Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03212404
Recruitment Status : Recruiting
First Posted : July 11, 2017
Last Update Posted : November 13, 2020
Sponsor:
Collaborator:
Novotech (Australia) Pty Limited
Information provided by (Responsible Party):
Checkpoint Therapeutics, Inc.

Tracking Information
First Submitted Date  ICMJE July 6, 2017
First Posted Date  ICMJE July 11, 2017
Last Update Posted Date November 13, 2020
Actual Study Start Date  ICMJE September 20, 2017
Estimated Primary Completion Date July 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 20, 2018)
  • Dose Limiting Toxicity [ Time Frame: Up to 4 weeks ]
  • Number of subjects with Treatment-Emergent Adverse Events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03 (or most current version) [ Time Frame: Screening through 4 weeks after study completion, an average of 6 months ]
  • Confirmed Objective Response Rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) [ Time Frame: Part 2 Only: Average of 6 months ]
Original Primary Outcome Measures  ICMJE
 (submitted: July 6, 2017)
  • Dose Limiting Toxicity [ Time Frame: Up to 4 weeks ]
  • Number of subjects with Treatment-Emergent Adverse Events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03 (or most current version) [ Time Frame: Screening through 4 weeks after study completion, an average of 6 months ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: November 20, 2018)
  • Confirmed Best Overall Response (BOR) as per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) [ Time Frame: Every 8 weeks for first 32 weeks, then 12 weeks through study completion, an average of 6 months ]
  • Duration of Response (DoR) as per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) [ Time Frame: Every 8 weeks for first 32 weeks, then 12 weeks through study completion, an average of 6 months ]
  • Objective response rate and duration of response (DOR) based on Modified RECIST 1.1 for immune based therapeutics [ Time Frame: Part 2 Only: Every 8 weeks for first 32 weeks, then 12 weeks through study completion, an average of 6 months ]
  • Overall Survival (OS) [ Time Frame: Part 2 Only: Every 8 weeks for first 32 weeks, then 12 weeks through study completion, an average of 6 months ]
  • Pharmacokinetic parameter: AUC (0-t) of CK-301 [ Time Frame: Baseline up to 12 weeks after study completion, an average of 6 months ]
  • Pharmacokinetic parameter: AUC (0-infinity) of CK-301 [ Time Frame: Baseline up to 12 weeks after study completion, an average of 6 months ]
  • Pharmacokinetic parameter: Cmax of CK-301 [ Time Frame: Baseline up to 12 weeks after study completion, an average of 6 months ]
  • Pharmacokinetic parameter: Tmax of CK-301 [ Time Frame: Baseline up to 12 weeks after study completion, an average of 6 months ]
  • Pharmacokinetic parameter: T(1/2) of CK-301 [ Time Frame: Baseline up to 12 weeks after study completion, an average of 6 months ]
  • Number of subjects with anti-CK-301 antibodies [ Time Frame: Baseline up to 12 weeks after study completion, an average of 6 months ]
Original Secondary Outcome Measures  ICMJE
 (submitted: July 6, 2017)
  • Confirmed Best Overall Response (BOR) as per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) [ Time Frame: Every 8 weeks for first 32 weeks, then 12 weeks through study completion, an average of 6 months ]
  • Confirmed Objective Response Rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) [ Time Frame: Every 8 weeks for first 32 weeks, then 12 weeks through study completion, an average of 6 months ]
  • Duration of Response (DoR) as per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) [ Time Frame: Every 8 weeks for first 32 weeks, then 12 weeks through study completion, an average of 6 months ]
  • Pharmacokinetic parameter: AUC (0-t) of CK-301 [ Time Frame: Baseline up to 12 weeks after study completion, an average of 6 months ]
  • Pharmacokinetic parameter: AUC (0-infinity) of CK-301 [ Time Frame: Baseline up to 12 weeks after study completion, an average of 6 months ]
  • Pharmacokinetic parameter: Cmax of CK-301 [ Time Frame: Baseline up to 12 weeks after study completion, an average of 6 months ]
  • Pharmacokinetic parameter: Tmax of CK-301 [ Time Frame: Baseline up to 12 weeks after study completion, an average of 6 months ]
  • Pharmacokinetic parameter: T(1/2) of CK-301 [ Time Frame: Baseline up to 12 weeks after study completion, an average of 6 months ]
  • Number of subjects with anti-CK-301 antibodies [ Time Frame: Baseline up to 12 weeks after study completion, an average of 6 months ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Official Title  ICMJE A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers
Brief Summary CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors. The primary objectives of this study are to assess the safety, tolerability and efficacy of CK-301 when administered intravenously as a single agent to subjects with selected recurrent or metastatic cancers.
Detailed Description This is a first-in-human, Phase 1, open-label, multicenter, dose-escalation study of CK-301 (cosibelimab), a fully human monoclonal IgG1 antibody targeting PD-L1. The study will consist of 3 periods: Screening (up to 28 days), Treatment (28-day cycles), and Follow-up (up to 6 months of visits with survival follow-up for select cohorts). Following the dose escalation portion of the study, additional evaluable subjects may be included in order to further characterize safety and efficacy at selected doses and/or in specific patient sub-groups.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Lung Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Small Cell
  • Malignant Mesothelioma, Advanced
  • Head and Neck Cancer
  • Melanoma
  • Merkel Cell Carcinoma
  • Renal Cell Carcinoma
  • Urothelial Carcinoma
  • Classical Hodgkin Lymphoma
  • Cutaneous Squamous Cell Carcinoma
  • Non Hodgkin Lymphoma
  • Endometrial Cancer
Intervention  ICMJE Drug: CK-301 (cosibelimab)
CK-301 will be administered in periods of 28-day cycles.
Study Arms  ICMJE Experimental: CK-301 (cosibelimab)
Part 1 - Dose Escalation; Part 2 - Dose Expansion
Intervention: Drug: CK-301 (cosibelimab)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: November 20, 2018)
500
Original Estimated Enrollment  ICMJE
 (submitted: July 6, 2017)
80
Estimated Study Completion Date  ICMJE December 2022
Estimated Primary Completion Date July 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Signed written informed consent.
  • Male or female subjects aged greater than or equal to 18 years.
  • For NSCLC: Histologically or cytologically confirmed diagnosis of unresectable recurrent or metastatic non-small cell lung cancer.
  • For CRC: Histologically confirmed diagnosis of recurrent or metastatic colorectal cancer assessed as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).
  • For EC: Histologically or cytologically confirmed advanced, recurrent or metastatic endometrial carcinoma.
  • For cSCC: Histologically confirmed diagnosis of unresectable or metastatic cutaneous squamous cell carcinoma not amenable to local therapy.
  • For SCLC: Histologically or cytologically confirmed diagnosis of unresectable small cell lung cancer.
  • For MPM: Histologically or cytologically confirmed diagnosis of unresectable malignant pleural or peritoneal mesothelioma.
  • For HNSCC: Histologically or cytologically confirmed diagnosis of recurrent or metastatic HNSCC (oral cavity, pharynx, larynx), stage III/IV and not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy).
  • For MEL: Histologically confirmed diagnosis of unresectable Stage III or metastatic melanoma not amenable to local therapy (excluding uveal or ocular melanoma).
  • For MCC: Histologically confirmed diagnosis of metastatic Merkel cell carcinoma not amenable to local therapy.
  • For RCC: Histologically confirmed diagnosis of renal cell carcinoma (with clear cell component) with advanced or metastatic disease that is not amenable to cure by surgery or other means.
  • For UC: Histologically or cytologically documented locally advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary bladder, urethra) not amenable to cure by surgery or other means.
  • For HL: Histologically confirmed primary diagnosis of classical Hodgkin's lymphoma.
  • For B-cell NHL: Histologically confirmed diagnosis of non-Hodgkin lymphoma.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at trial entry and an estimated life expectancy of at least 3 months
  • Must have at least one measurable lesion based on RECIST 1.1.
  • Have provided a formalin fixed tumor tissue sample from a biopsy of a tumor lesion either at the time of or after the diagnosis of metastatic disease has been made AND from a site not previously irradiated.
  • Adequate hematological, hepatic and renal function as defined in the protocol.
  • Effective contraception for both male and female subjects if the risk of conception exists.
  • Other protocol defined inclusion criteria could apply.

Exclusion Criteria:

  • Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.
  • Concurrent treatment with a non-permitted drug.
  • History of severe hypersensitivity reactions to other monoclonal antibodies.
  • Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast, or localized prostate cancer.
  • Chemotherapy, radioactive, biological cancer therapy, or tyrosine kinase inhibitor (TKI) therapy, within four weeks prior to the first dose of study drug, or who has not recovered to NCI CTCAE Grade 1 or better from the AEs due to cancer therapeutics administered more than four weeks earlier.
  • Significant acute or chronic infections as defined in the protocol.
  • Active or history of interstitial lung disease (ILD), or has had a history of pneumonitis that has required oral or IV steroids.
  • Active or suspected autoimmune disease or a documented history of autoimmune disease.
  • Known current drug or alcohol abuse.
  • Underlying medical conditions that will make the administration of study drug hazardous or obscure the interpretation of toxicity determination or adverse events.
  • Use of other investigational therapy within 28 days before study drug administration.
  • Pregnant or breastfeeding.
  • Uncontrolled or significant cardiovascular disease.
  • Psychiatric illness or social situation that would preclude study compliance.
  • Receipt of live, attenuated vaccine within 28 days prior to the first dose of study drug.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: James Oliviero 001-212-574-2830 info@checkpointtx.com
Listed Location Countries  ICMJE Australia,   France,   New Zealand,   Poland,   Russian Federation,   South Africa,   Spain,   Thailand,   Ukraine
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03212404
Other Study ID Numbers  ICMJE CK-301-101
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Checkpoint Therapeutics, Inc.
Study Sponsor  ICMJE Checkpoint Therapeutics, Inc.
Collaborators  ICMJE Novotech (Australia) Pty Limited
Investigators  ICMJE Not Provided
PRS Account Checkpoint Therapeutics, Inc.
Verification Date November 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP